Singapore markets open in 6 hours 48 minutes

AKRO May 2024 22.500 put

OPR - OPR Delayed price. Currency in USD
Add to watchlist
1.95000.0000 (0.00%)
As of 11:58AM EDT. Market open.
Full screen
Previous close1.9500
Open1.5500
Bid0.0000
Ask3.0000
Strike22.50
Expiry date2024-05-17
Day's range1.5500 - 2.1000
Contract rangeN/A
Volume38
Open interest196
  • GuruFocus.com

    Akero Therapeutics Inc (AKRO) Q1 2024 Earnings: Misses Analyst Forecast Amid Continued ...

    Comprehensive Analysis of Financial Performance and Strategic Progress

  • GlobeNewswire

    Akero Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

    -- Statistically significant week 96 results from the Phase 2b HARMONY study of EFX in patients with pre-cirrhotic MASH reported during the first quarter of 2024 -- -- Phase 3 SYNCHRONY Histology and SYNCHRONY Real-World studies in patients with pre-cirrhotic MASH (F2-F3) continue to enroll; SYNCHRONY Outcomes study in patients with compensated cirrhosis due to MASH (F4) on track to be initiated in second quarter of 2024 -- SOUTH SAN FRANCISCO, Calif., May 10, 2024 (GLOBE NEWSWIRE) -- Akero Ther

  • GlobeNewswire

    Akero Therapeutics to Present at the BofA Securities 2024 Health Care Conference

    SOUTH SAN FRANCISCO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the BofA Securities 2024 Health Care Conference on Tuesday, May 14, 2024, at 5:00 p.m. P.T. in Las Vegas, NV. A live webcast of the Company presentation will be available through the investor relations sec